Lord, Abbett & Co
KERX

Lord, Abbett & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Lord, Abbett & Co’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-391,277
Closed -$6.02M – 1067
2014
Q2 		$6.02M Sell
391,277
-39,924
-9% -$566K 0.01% 765
2014
Q1 		$7.35M Sell
431,201
-411,267
-49% -$6.2M 0.02% 725
2013
Q4 		$10.9M Sell
842,468
-51,302
-6% -$613K 0.02% 648
2013
Q3 		$9.03M Buy
893,770
+252,537
+39% +$2.25M 0.02% 667
2013
Q2 		$4.79M Buy
+641,233
New +$5.01M 0.01% 814

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Lord, Abbett & Co's KERX Position: Q3 2014 in Review

Lord, Abbett & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2014, closing a stake of 391,277 shares — an estimated $6.02M sold.

Lord, Abbett & Co first reported a position in KERX in Q2 2013 and held it in 5 quarters. The position peaked at $10.9M in Q4 2013. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • Lord, Abbett & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 391,277 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $6.02M.
  • Lord, Abbett & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 5 quarters.
  • Lord, Abbett & Co's Keryx Biopharmaceuticals Inc position peaked at $10.9M in Q4 2013.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on Lord, Abbett & Co's 13F filing for Q3 2014, filed 14 Nov 2014.